Nutriband Inc (OTCQB: NTRB), a Nevada Corporation, closed the last session at $14.990, gaining 24.92% and bringing its market cap to $95.28M. Nutriband stock has 25.00M shares outstanding and 0.54M float, according to the pink sheets company. Recently announced developments might provide us with more insight into the NTRB stock, as it was on an upbeat without current news.
What has NTRB been up to recently?
In its current capacity, Nutriband focuses on developing transdermal pharmaceutical products. NTRB is developing its abuse-deterrent fentanyl transdermal system for clinical use in managing chronic pain patients requiring opioid therapy as a first-of-its-kind drug that is not subject to abuse. With NTRB’s product, there is a unique method to prevent fentanyl patches from being abused and misused in order to combat the opioid crisis.
Nutriband filed its audited financial reports on form 8-K/A this year with the SEC. Its reports covered both itself and its subsidiaries, along with pro forma financial statements for the NTRB and its subsidiaries. Pocono Coated Products LLC and Active Intelligence both are wholly owned subsidiaries of Nutriband.
Other developments from NTRB:
Nutriband (NTRB) also signed an exclusive licensing agreement with RAMBAM Med Tech Ltd, which operates as part of RAMBAM Hospital, northern Israel’s largest medical center. As per the agreements, NTRB is working with RAMBAM to develop a medical device dedicated to liquifying drugs for patients with swallowing difficulties.